GO:0004671 protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004671 describes the enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to the C-terminal isoprenylcysteine of proteins, producing a methyl ester and S-adenosyl-L-homocysteine.
• In Saccharomyces cerevisiae, this activity depends on the STE14 gene product, establishing the first genetic link between the enzyme and the methylation of farnesylcysteine.
• The integral membrane methyltransferase ICMT (isoprenylcysteine carboxyl methyltransferase) catalyzes this reaction in humans, and its crystal structure revealed the catalytic mechanism and membrane topology.
• Small-molecule inhibitors of ICMT, such as cysmethynil, show antitumor activity in cancer cells, highlighting the enzyme as a potential therapeutic target.
• ICMT-mediated methylation regulates small GTPases including RhoA, Rac1, and K-Ras, influencing cell signaling, ROS generation, and insulin secretion.
• Research on this activity spans enzymology, structural biology, and disease models, with methods including biochemical assays, X-ray crystallography, and CRISPR-based gene editing.
Description
Protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity (GO:0004671) is a molecular function that catalyzes the final step in the post-translational processing of CAAX-motif proteins. This methylation reaction converts the C-terminal isoprenylcysteine residue of farnesylated or geranylgeranylated proteins into a methyl ester, using S-adenosyl-L-methionine as the methyl donor. The activity is essential for the proper localization and function of small GTPases such as Ras, Rho, and Rac, which are key regulators of cell proliferation, cytoskeletal dynamics, and signal transduction. The enzyme responsible for this activity, isoprenylcysteine carboxyl methyltransferase (ICMT), is an integral membrane protein of the endoplasmic reticulum. Its discovery in yeast as the STE14 gene product provided the first genetic evidence for the enzyme's role in farnesylcysteine methylation. Subsequent biochemical studies purified the activity from bovine brain and kidney membranes, confirming its widespread occurrence in mammalian tissues. The crystal structure of ICMT revealed a unique membrane-embedded active site that facilitates the methyl transfer reaction. Dysregulation of this methylation activity has been implicated in cancer, where ICMT inhibitors reduce tumor cell growth, and in metabolic processes such as glucose-induced Rac1 activation and insulin secretion. Understanding GO:0004671 is therefore critical for researchers studying protein prenylation, membrane trafficking, and related diseases. This article provides a comprehensive overview of the term, its mechanism, associated genes, and experimental approaches for investigation.
protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity At A Glance
| GO ID | GO:0004671 |
|---|---|
| GO term | protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity |
| Ontology | molecular_function |
| Synonym | isoprenylcysteine carboxylmethyltransferase activity; prenylcysteine carboxyl methyltransferase activity; farnesyl cysteine C-terminal methyltransferase activity |
| Major function | Catalyzes the methylation of the C-terminal isoprenylcysteine residue of proteins using S-adenosyl-L-methionine as methyl donor |
| Reaction | S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine = S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester |
| Enzyme class | Transferase; methyltransferase |
| Subcellular location | Endoplasmic reticulum membrane (integral membrane protein) |
| Representative gene | ICMT (human), STE14 (Saccharomyces cerevisiae) |
What Is GO:0004671?
GO:0004671 describes the catalytic activity of an enzyme that transfers a methyl group from S-adenosyl-L-methionine to the C-terminal S-farnesyl-L-cysteine residue of a protein, yielding S-adenosyl-L-homocysteine and a protein C-terminal S-farnesyl-L-cysteine methyl ester. This activity is also known as isoprenylcysteine carboxylmethyltransferase (ICMT) activity and acts on prenylated proteins, typically those ending with a CAAX motif after proteolytic removal of the -AAX tripeptide.
Why Is protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity Important in Cell Biology?
GO:0004671 is critical because it governs the final maturation step of prenylated proteins, a modification that controls membrane association and function of key signaling molecules such as Ras and Rho GTPases. This methylation enhances the hydrophobicity of the prenylcysteine, facilitating stable membrane anchoring and proper protein-protein interactions. In yeast, loss of the STE14 gene product abolishes farnesylcysteine methyltransferase activity, demonstrating its essential role in the pathway. In humans, ICMT inhibitors have shown antitumor activity, underscoring the therapeutic relevance of this activity in cancer. Furthermore, the enzyme is involved in metabolic signaling, as it facilitates glucose-induced Rac1 activation and insulin secretion in pancreatic beta cells. Thus, understanding GO:0004671 offers insights into fundamental cell biology and potential treatments for cancer and metabolic disorders.
• Regulates membrane localization and function of Ras and Rho family GTPases, which are frequently mutated in cancers.
• Required for the final step of CAAX protein processing, affecting cell proliferation, differentiation, and survival.
• ICMT inhibitors like cysmethynil reduce tumor growth in cancer cell models, indicating a target for anticancer therapy.
• Modulates glucose-stimulated insulin secretion through Rac1 activation in pancreatic beta cells.
• Influences RhoA methylation and downstream signaling, with implications for cell migration and metastasis.
• Conserved from yeast to humans, with STE14 as the founding member in Saccharomyces cerevisiae.
• Biochemical properties have been characterized from bovine brain and kidney, aiding drug discovery.
• Trypanosoma brucei enzyme prefers farnesylated substrates, suggesting species-specific differences relevant to parasitic diseases.
Molecular Mechanism of protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs onto a protein that has a special fat-like tag at its end.
ICMT recognizes prenylated proteins that have undergone proteolytic removal of the -AAX tripeptide, exposing a C-terminal isoprenylcysteine. The enzyme binds the farnesyl or geranylgeranyl moiety and the cysteine residue, positioning the carboxyl group for methylation. The crystal structure of ICMT revealed a hydrophobic pocket that accommodates the isoprenyl chain and a catalytic site near the membrane interface. In Trypanosoma brucei, the enzyme prefers farnesylated substrates, indicating substrate specificity variations across species.
Catalytic Methyl Transfer
In simple terms: The enzyme takes a methyl group from a donor molecule and attaches it to the protein's tail.
The catalytic mechanism involves the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the C-terminal carboxylate of the isoprenylcysteine, forming a methyl ester and releasing S-adenosyl-L-homocysteine (SAH). Structural studies of ICMT identified key residues that stabilize the transition state and facilitate deprotonation of the cysteine carboxylate. The reaction is thought to proceed via a direct nucleophilic attack, with the membrane environment influencing the pKa of the substrate.
Cofactors and Energetics
In simple terms: The reaction uses a common cellular molecule as the methyl donor and doesn't require ATP.
S-adenosyl-L-methionine (SAM) serves as the methyl donor, and the reaction produces S-adenosyl-L-homocysteine (SAH) as a byproduct. This is a typical methyltransferase reaction that does not require ATP or other energy sources. The enzyme's activity is dependent on the availability of SAM and the redox state of the cell, although direct regulation by metabolites has not been extensively characterized.
Regulation and Inhibition
In simple terms: The enzyme can be turned off by specific inhibitor molecules, which is useful for research and therapy.
ICMT activity can be inhibited by small molecules such as cysmethynil, which competes with SAM binding and reduces methylation of Ras and Rho proteins. This inhibition leads to mislocalization of these GTPases and inhibits tumor cell growth. Additionally, the activity is regulated by the availability of prenylated substrates, which depends on upstream farnesyltransferase and geranylgeranyltransferase activities. Carboxylesterase I has been shown to control RhoA methylation by modulating the levels of methylated RhoA.
Key Genes Involved in GO:0004671 protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity
The following genes encode proteins that either catalyze or regulate the methylation of isoprenylcysteine residues, or are substrates of this activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ICMT | Catalyzes the methylation of isoprenylcysteine residues on CAAX proteins | Primary enzyme for GO:0004671; target for cancer therapeutics |
| STE14 | Yeast homolog of ICMT; required for farnesylcysteine methyltransferase activity | Foundational genetic model for the activity |
| RHOa | Small GTPase substrate; methylation regulates membrane localization and signaling | Implicated in cancer and cell migration |
| RAC1 | Small GTPase substrate; methylation required for glucose-induced activation | Role in insulin secretion and ROS generation |
| KRAS | Small GTPase substrate; methylation affects plasma membrane targeting | Frequently mutated in cancers; target of ICMT inhibitors |
| HRAS | Small GTPase substrate; methylation required for full transforming activity | Model for studying prenylation and cancer |
| NRAS | Small GTPase substrate; methylation influences membrane binding | Relevant to melanoma and leukemia research |
| CDC42 | Small GTPase substrate; methylation affects cytoskeletal dynamics | Involved in cell polarity and migration |
| RAB proteins | Substrates with C-terminal prenylation; methylation may affect trafficking | Potential role in vesicle transport |
| PGGT1B | Geranylgeranyltransferase subunit; adds prenyl groups to substrates | Upstream of ICMT in the pathway |
| FNTA | Farnesyltransferase subunit; prenylates CAAX proteins | Provides substrates for ICMT |
| RCE1 | Protease that removes -AAX tripeptide, exposing isoprenylcysteine | Essential for generating ICMT substrate |
| PCMT1 | Protein carboxyl methyltransferase, distinct from ICMT but related | May have overlapping functions in methylation |
| TbPCMT | Trypanosoma brucei prenylated-protein carboxyl methyltransferase | Parasite-specific enzyme with substrate preference |
| CES1 | Carboxylesterase I; regulates RhoA methylation levels | Modulates methylation status indirectly |
| ICMT (bovine) | Partially purified from bovine brain | Biochemical characterization of the activity |
| ICMT (kidney) | C-terminal protein carboxyl methyltransferase from kidney membranes | Functional size determination |
How Is protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity Regulated?
The activity of protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase is primarily regulated at the level of substrate availability and enzyme expression. Upstream enzymes RCE1 and prenyltransferases generate the prenylated cysteine substrate, and their activities influence the rate of methylation. ICMT expression can be induced by cellular stress and growth factors, although the exact transcriptional regulators are not fully defined. Small-molecule inhibitors such as cysmethynil directly inhibit ICMT activity by competing with SAM binding. Additionally, carboxylesterase I has been shown to control RhoA methylation, suggesting a regulatory role in methylation turnover. In pancreatic beta cells, glucose stimulation enhances Rac1 methylation and activation, linking metabolic status to ICMT function.
protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ICMT | Cancer (various solid tumors and leukemias) | ICMT knockout or inhibitor-treated cancer cell lines; xenograft mouse models |
| RHOa | Cancer metastasis and cell migration | RhoA point-mutant knock-in cells; CRISPR knockout of ICMT |
| RAC1 | Type 2 diabetes and insulin secretion defects | INS 832/13 beta cells with ICMT knockdown or knockout |
| KRAS | Pancreatic, lung, and colorectal cancers | Kras-driven mouse models with conditional Icmt deletion |
| TbPCMT | African sleeping sickness | Trypanosoma brucei cultures treated with ICMT inhibitors |
Cancer
ICMT is overexpressed in several cancers and is required for the oncogenic activity of Ras and Rho GTPases. Inhibition of ICMT with cysmethynil reduces tumor cell proliferation and induces apoptosis in cancer cell lines, highlighting its potential as a therapeutic target. Methylation of RhoA by ICMT contributes to cell migration and metastasis, and its dysregulation is associated with poor prognosis in some cancers.
Metabolic Disorders
In pancreatic beta cells, ICMT-mediated methylation of Rac1 is necessary for glucose-induced Rac1 activation, ROS generation, and insulin secretion. Dysregulation of this pathway may contribute to impaired insulin secretion in type 2 diabetes.
Parasitic Infections
Trypanosoma brucei expresses a prenylated-protein carboxyl methyltransferase that prefers farnesylated substrates, suggesting that ICMT-like enzymes are potential drug targets for African sleeping sickness.
From protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of complete loss of ICMT on cell viability? | ICMT knockout cell lines generated by CRISPR/Cas9 |
| How does a specific catalytic residue mutation affect methyltransferase activity? | Point-mutation knock-in of ICMT catalytic residues |
| Does tagging ICMT with a fluorescent protein affect its localization? | Knock-in of GFP or FLAG tag at the endogenous ICMT locus |
| What happens when ICMT is overexpressed in cancer cells? | ICMT overexpression stable cell lines |
| How does ICMT inhibition affect Ras membrane localization? | Cells treated with cysmethynil or ICMT knockout |
| What is the role of ICMT in glucose-stimulated insulin secretion? | INS 832/13 beta cells with ICMT knockdown |
How to Study the protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro methyltransferase assay | Enzymatic transfer of methyl group from SAM to protein substrate | Purification and kinetic characterization of ICMT |
| X-ray crystallography | Three-dimensional structure of ICMT | Understanding catalytic mechanism and membrane topology |
| Immunoblotting with methylation-specific antibodies | Levels of methylated GTPases in cells | Studying regulation of RhoA and Rac1 methylation |
| Metabolic labeling with [3H]mevalonate | Prenylation and methylation of proteins in vivo | Tracking post-translational processing of CAAX proteins |
| CRISPR knockout screens | Genes required for cell growth in presence of ICMT inhibitors | Identifying synthetic lethal targets |
| Fluorescence microscopy | Subcellular localization of ICMT and substrate GTPases | Assessing effects of methylation on membrane targeting |
| Small-molecule inhibitor treatment | Inhibition of ICMT activity and downstream effects | Testing anticancer activity of cysmethynil |
| qRT-PCR | Expression levels of ICMT and related genes | Correlating expression with disease states |
Biochemical Methyltransferase Assays
In vitro methyltransferase activity can be measured using recombinant ICMT or membrane fractions incubated with S-adenosyl-L-[methyl-3H]methionine and a farnesylated protein substrate. The incorporation of radioactive methyl groups into the substrate is quantified by scintillation counting or autoradiography. This method was used to purify and characterize the enzyme from bovine brain and kidney.
Structural Biology
X-ray crystallography of ICMT provided the first atomic view of the enzyme, revealing its membrane topology and catalytic mechanism. The structure showed a unique fold with the active site embedded in the membrane, explaining how it accesses the hydrophobic isoprenylcysteine substrate.
Cell-Based Methylation Assays
Methylation of specific GTPases such as RhoA and Rac1 can be assessed in cell lysates using antibodies that specifically recognize the methylated form, or by metabolic labeling with [3H]mevalonate followed by immunoprecipitation. These assays have been used to study the regulation of RhoA methylation by carboxylesterase I and the role of ICMT in Rac1 activation.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to ICMT inhibitors or that regulate the methylation pathway. Such screens can uncover synthetic lethal interactions and novel regulators of GO:0004671 activity.
How CRISPR Can Be Used to Study GO:0004671 protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity
Knockout
CRISPR/Cas9-mediated knockout of ICMT or STE14 can completely abolish protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity, leading to mislocalization of Ras and Rho GTPases and inhibition of cell growth. Knockout cell lines are valuable for studying the downstream consequences of loss of methylation and for validating inhibitor specificity.
Point Mutation
Introducing point mutations in the catalytic domain of ICMT (e.g., residues involved in SAM binding or catalysis) can dissect the enzymatic mechanism. Such mutants can be knocked into the endogenous locus to study the effects of specific catalytic defects on protein function and cellular signaling.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins (e.g., GFP) at the ICMT locus allows for real-time imaging and biochemical purification of the enzyme. Tagged knock-in models help track ICMT localization and interactions under physiological conditions.
Overexpression
Overexpression of wild-type or mutant ICMT in cancer cell lines can enhance methylation of substrate GTPases and promote oncogenic signaling. Overexpression models are useful for testing the effects of increased ICMT activity on cell proliferation, migration, and tumor formation.
How EDITGENE Supports protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity Research
Researchers studying protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in methylation-dependent processes, such as Ras localization or insulin secretion. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes in the ICMT pathway.
Contact EDITGENE today to design your custom CRISPR model for protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity research.
Frequently Asked Questions About protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity
What is protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity?
It is the enzymatic activity that adds a methyl group to the C-terminal isoprenylcysteine of proteins, a final step in CAAX protein processing, as defined by GO:0004671.
What genes are involved in protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity?
The primary gene is ICMT in humans and STE14 in yeast, which encode the enzyme responsible for this activity.
What is the role of ICMT in cancer?
ICMT is required for the membrane localization and oncogenic function of Ras and Rho GTPases; its inhibition reduces tumor cell growth.
How is protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity regulated?
It is regulated by substrate availability, enzyme expression, and small-molecule inhibitors such as cysmethynil.
What diseases are associated with GO:0004671?
Dysregulation is linked to cancer, type 2 diabetes, and parasitic infections such as African sleeping sickness.
What is the reaction catalyzed by GO:0004671?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine = S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester.
Which proteins are substrates of ICMT?
Small GTPases such as K-Ras, N-Ras, H-Ras, RhoA, Rac1, and CDC42 are substrates.
How can I study protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity in the lab?
Common methods include in vitro methyltransferase assays, X-ray crystallography, and CRISPR knockout cell models.
What is the difference between ICMT and STE14?
STE14 is the yeast homolog of human ICMT; both catalyze the same methylation reaction but in different organisms.
Are there inhibitors of protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity?
Yes, cysmethynil is a small-molecule inhibitor that competes with SAM and shows antitumor activity.
Conclusion
GO:0004671 represents a critical enzymatic activity in the post-translational processing of prenylated proteins, with far-reaching implications for cell signaling, cancer, and metabolic regulation. The conserved mechanism, from yeast STE14 to human ICMT, underscores its fundamental importance. Continued research using CRISPR-based models and biochemical assays will further illuminate its therapeutic potential.
References
- 1. Hrycyna CA et al.. 1990. Farnesyl cysteine C-terminal methyltransferase activity is dependent upon the STE14 gene product in Saccharomyces cerevisiae.. Mol Cell Biol 10(10):5071-6 PMID: 2204804
- 2. Winter-Vann AM et al.. 2005. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.. Proc Natl Acad Sci U S A 102(12):4336-41 PMID: 15784746
- 3. Boivin D et al.. 1994. Functional size of C-terminal protein carboxyl methyltransferase from kidney basolateral plasma membranes.. Biochim Biophys Acta 1207(1):114-9 PMID: 8043600
- 4. Yoo BC et al.. 1998. Partial purification of protein farnesyl cysteine carboxyl methyltransferase from bovine brain.. Exp Mol Med 30(4):227-34 PMID: 9894153
- 5. Yang J et al.. 2011. Mechanism of isoprenylcysteine carboxyl methylation from the crystal structure of the integral membrane methyltransferase ICMT.. Mol Cell 44(6):997-1004 PMID: 22195972
- 6. Buckner FS et al.. 2002. Trypanosoma brucei prenylated-protein carboxyl methyltransferase prefers farnesylated substrates.. Biochem J 367(Pt 3):809-16 PMID: 12141948
- 7. Cushman I et al.. 2013. Control of RhoA methylation by carboxylesterase I.. J Biol Chem 288(26):19177-83 PMID: 23658012
- 8. Jayaram B et al.. 2011. Isoprenylcysteine carboxyl methyltransferase facilitates glucose-induced Rac1 activation, ROS generation and insulin secretion in INS 832/13 β-cells.. Islets 3(2):48-57 PMID: 21346419
